Skip to main content
. 2022 Jul;50(7):942–956. doi: 10.1124/dmd.121.000781

Fig. 10.

Fig. 10.

P-gp and Bcrp expression in cerebral cortex, hippocampus, and cerebellum after BMP-9 treatment. Animals were administered a single dose of BMP-9 (1.0 μg/ml) or LDN193189 (10 mg/kg) at 1 hour prior to receiving a single dose of BMP-9 (1.0 μg/ml). After 6 hours, animals were euthanized and brain microvessels isolated and prepared for western blot analysis. Isolated microvessels (10 μg) were resolved on a 10% or 4%–12% SDS-polyacrylamide gel, transferred to a polyvinylidene difluoride membrane and analyzed for protein expression of P-gp (A) or Bcrp (B) in cerebral cortex, hippocampus, or cerebellum (C). Each lane pair on the depicted western blot corresponds to a microvessel sample obtained from a single experimental animal. Relative levels of P-gp or Bcrp protein expression were determined by densitometric analysis and normalized to tubulin (i.e., the loading control). Results are expressed as mean ± S.D. from at least two independent experiments, where each treatment group consisted of normalized data from eight individual animals (n = 8). Asterisks represent data points that were significantly different from control (**p < 0.01).